Yuhan Corp. Asset Resilience Ratio
Yuhan Corp. asset resilience ratio. Yuhan Corp. (000100) has an Asset Resilience Ratio of 0.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000100 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Yuhan Corp. (2000–2025)
Asset resilience ratio of Yuhan Corp. from 2000 to 2025. This chart shows how Yuhan Corp.'s Asset Resilience Ratio has changed over time. Read Yuhan Corp. total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Yuhan Corp.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Yuhan Corp. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩29.52 Billion | 0.92% |
| Total Liquid Assets | ₩29.52 Billion | 0.92% |
Asset Resilience Insights
- Limited Liquidity: Yuhan Corp. maintains only 0.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yuhan Corp. Industry Peers by Asset Resilience Ratio
Compare Yuhan Corp.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Yuhan Corp. Asset Resilience Ratio by Year (2000–2025)
Yuhan Corp. asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Yuhan Corp..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.92% | ₩29.52 Billion ≈ $20.00 Million |
₩3.22 Trillion ≈ $2.18 Billion |
+0.09pp |
| 2024-12-31 | 0.82% | ₩24.23 Billion ≈ $16.42 Million |
₩2.94 Trillion ≈ $1.99 Billion |
+0.01pp |
| 2023-12-31 | 0.81% | ₩22.75 Billion ≈ $15.41 Million |
₩2.81 Trillion ≈ $1.91 Billion |
-1.40pp |
| 2022-12-31 | 2.21% | ₩54.68 Billion ≈ $37.06 Million |
₩2.47 Trillion ≈ $1.68 Billion |
-5.22pp |
| 2021-12-31 | 7.44% | ₩183.22 Billion ≈ $124.16 Million |
₩2.46 Trillion ≈ $1.67 Billion |
+3.59pp |
| 2020-12-31 | 3.85% | ₩92.11 Billion ≈ $62.42 Million |
₩2.39 Trillion ≈ $1.62 Billion |
-2.81pp |
| 2019-12-31 | 6.66% | ₩140.94 Billion ≈ $95.51 Million |
₩2.12 Trillion ≈ $1.43 Billion |
-4.10pp |
| 2018-12-31 | 10.76% | ₩233.84 Billion ≈ $158.47 Million |
₩2.17 Trillion ≈ $1.47 Billion |
-0.94pp |
| 2017-12-31 | 11.70% | ₩245.00 Billion ≈ $166.03 Million |
₩2.09 Trillion ≈ $1.42 Billion |
-0.11pp |
| 2016-12-31 | 11.81% | ₩241.58 Billion ≈ $163.71 Million |
₩2.05 Trillion ≈ $1.39 Billion |
+10.18pp |
| 2015-12-31 | 1.63% | ₩30.66 Billion ≈ $20.78 Million |
₩1.88 Trillion ≈ $1.27 Billion |
-15.20pp |
| 2014-12-31 | 16.83% | ₩271.99 Billion ≈ $184.32 Million |
₩1.62 Trillion ≈ $1.10 Billion |
+11.27pp |
| 2013-12-31 | 5.56% | ₩84.16 Billion ≈ $57.03 Million |
₩1.51 Trillion ≈ $1.03 Billion |
-5.54pp |
| 2012-12-31 | 11.10% | ₩155.80 Billion ≈ $105.58 Million |
₩1.40 Trillion ≈ $950.85 Million |
+0.19pp |
| 2011-12-31 | 10.92% | ₩143.48 Billion ≈ $97.23 Million |
₩1.31 Trillion ≈ $890.52 Million |
-5.38pp |
| 2010-12-31 | 16.30% | ₩204.61 Billion ≈ $138.66 Million |
₩1.26 Trillion ≈ $850.84 Million |
+8.95pp |
| 2009-12-31 | 7.35% | ₩83.35 Billion ≈ $56.49 Million |
₩1.13 Trillion ≈ $769.03 Million |
-0.69pp |
| 2008-12-31 | 8.04% | ₩83.48 Billion ≈ $56.58 Million |
₩1.04 Trillion ≈ $704.04 Million |
+0.72pp |
| 2007-12-31 | 7.31% | ₩72.94 Billion ≈ $49.43 Million |
₩997.19 Billion ≈ $675.78 Million |
+2.23pp |
| 2006-12-31 | 5.09% | ₩47.91 Billion ≈ $32.47 Million |
₩941.40 Billion ≈ $637.97 Million |
-4.19pp |
| 2005-12-31 | 9.28% | ₩83.42 Billion ≈ $56.54 Million |
₩898.67 Billion ≈ $609.01 Million |
+0.93pp |
| 2004-12-31 | 8.35% | ₩63.87 Billion ≈ $43.29 Million |
₩764.90 Billion ≈ $518.36 Million |
-0.88pp |
| 2003-12-31 | 9.23% | ₩60.90 Billion ≈ $41.27 Million |
₩659.58 Billion ≈ $446.99 Million |
-4.81pp |
| 2002-12-31 | 14.04% | ₩88.60 Billion ≈ $60.04 Million |
₩631.04 Billion ≈ $427.64 Million |
-1.03pp |
| 2001-12-31 | 15.07% | ₩87.95 Billion ≈ $59.60 Million |
₩583.76 Billion ≈ $395.60 Million |
-0.19pp |
| 2000-12-31 | 15.25% | ₩84.83 Billion ≈ $57.49 Million |
₩556.14 Billion ≈ $376.89 Million |
-- |
About Yuhan Corp.
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and ana… Read more